Literature DB >> 22810581

Where should we draw the line between quality of care and other ethical concerns related to medical registries and biobanks?

Mats Hansson1.   

Abstract

Together with large biobanks of human samples, medical registries with aggregated data from many clinical centers are vital parts of an infrastructure for maintaining high standards of quality with regard to medical diagnosis and treatment. The rapid development in personalized medicine and pharmaco-genomics only underscores the future need for these infrastructures. However, registries and biobanks have been criticized as constituting great risks to individual privacy. In this article, I suggest that quality with regard to diagnosis and treatment is an inherent, morally normative requirement of health care, and argue that quality concerns in this sense may be balanced with privacy concerns.

Entities:  

Mesh:

Year:  2012        PMID: 22810581     DOI: 10.1007/s11017-012-9229-x

Source DB:  PubMed          Journal:  Theor Med Bioeth        ISSN: 1386-7415


  24 in total

1.  Genetics. No longer de-identified.

Authors:  Amy L McGuire; Richard A Gibbs
Journal:  Science       Date:  2006-04-21       Impact factor: 47.728

Review 2.  Medication adherence in heart failure.

Authors:  Paul J Hauptman
Journal:  Heart Fail Rev       Date:  2007-05-04       Impact factor: 4.214

Review 3.  Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.

Authors:  Hans-Georg Eichler; Francesco Pignatti; Bruno Flamion; Hubert Leufkens; Alasdair Breckenridge
Journal:  Nat Rev Drug Discov       Date:  2008-09-12       Impact factor: 84.694

4.  Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer.

Authors:  K L Wallin; F Wiklund; T Angström; F Bergman; U Stendahl; G Wadell; G Hallmans; J Dillner
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

5.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study.

Authors:  M Lehtinen; J Dillner; P Knekt; T Luostarinen; A Aromaa; R Kirnbauer; P Koskela; J Paavonen; R Peto; J T Schiller; M Hakama
Journal:  BMJ       Date:  1996-03-02

6.  A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Authors:  Carolina Holmén; Fredrik Piehl; Jan Hillert; Anna Fogdell-Hahn; Malin Lundkvist; Elin Karlberg; Petra Nilsson; Charlotte Dahle; Nils Feltelius; Anders Svenningsson; Jan Lycke; Tomas Olsson
Journal:  Mult Scler       Date:  2011-01-12       Impact factor: 6.312

7.  Are cancer registries unconstitutional?

Authors:  Robert H McLaughlin; Christina A Clarke; Lavera M Crawley; Sally L Glaser
Journal:  Soc Sci Med       Date:  2010-02-12       Impact factor: 4.634

Review 8.  Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.

Authors:  Peter H O'Donnell; Mark J Ratain
Journal:  Mol Oncol       Date:  2012-01-21       Impact factor: 6.603

9.  "Building" a history rather than "taking" one: a perspective on information sharing during the medical interview.

Authors:  Paul Haidet; Debora A Paterniti
Journal:  Arch Intern Med       Date:  2003-05-26

10.  Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

Authors:  Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

View more
  2 in total

1.  Rare diseases and now rare data?

Authors:  Deborah Mascalzoni; Bartha Maria Knoppers; Ségolène Aymé; Matteo Macilotti; Hugh Dawkins; Simon Woods; Mats G Hansson
Journal:  Nat Rev Genet       Date:  2013-06       Impact factor: 53.242

2.  Rare disease research: Breaking the privacy barrier.

Authors:  Deborah Mascalzoni; Angelo Paradiso; Matts Hansson
Journal:  Appl Transl Genom       Date:  2014-04-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.